{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:54:24Z","timestamp":1787169264401,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["58\/02\/2022\/PHA\/BMS"],"award-info":[{"award-number":["58\/02\/2022\/PHA\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04921-5","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:35:44Z","timestamp":1778492144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the efficacy of XAV939 and LF3 in targeting \u03b2-catenin signalling in gallbladder cancer cell lines"],"prefix":"10.1007","volume":"17","author":[{"given":"Akanksha","family":"Kashyap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh Mohammad","family":"Umar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arundhathi J. R.","family":"Dev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Manav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasenjit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Chethan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra Prakash","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"4921_CR1","doi-asserted-by":"crossref","unstructured":"Guo H, Zhang D, Li Z, Liu S, Wang R. Global burden of gallbladder cancer in 2022 and predictions to 2042. Dig Liver Dis. 2025;S1590865825002439.","DOI":"10.1016\/j.dld.2025.02.007"},{"key":"4921_CR2","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99\u2013109.","journal-title":"Clin Epidemiol"},{"key":"4921_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4103\/0019-509X.197723","volume":"53","author":"SS Mhatre","year":"2016","unstructured":"Mhatre SS, Nagrani RT, Budukh A, Chiplunkar S, Badwe R, Patil P, et al. Place of birth and risk of gallbladder cancer in India. Indian J Cancer. 2016;53:304.","journal-title":"Indian J Cancer"},{"key":"4921_CR4","first-page":"49","volume":"3","author":"N Sikdar","year":"2016","unstructured":"Sikdar N. The geographical, ethnic variations and risk factors of gallbladder carcinoma: a worldwide view. J Investig Genomics. 2016;3:49\u201354.","journal-title":"J Investig Genomics"},{"key":"4921_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4103\/ijmr.IJMR_201_19","volume":"154","author":"K Mishra","year":"2021","unstructured":"Mishra K, Behari A, Shukla P, Tsuchiya Y, Endoh K, Asai T, et al. Risk factors for gallbladder cancer development in northern India: A gallstones-matched, case-control study. Indian J Med Res. 2021;154:699\u2013706.","journal-title":"Indian J Med Res"},{"key":"4921_CR6","doi-asserted-by":"publisher","first-page":"7813","DOI":"10.3748\/wjg.v27.i45.7813","volume":"27","author":"S Goel","year":"2021","unstructured":"Goel S, Aggarwal A, Iqbal A, Talwar V, Mitra S, Singh S. Multimodality management of gallbladder cancer can lead to a better outcome: Experience from a tertiary care oncology centre in North India. World J Gastroenterol. 2021;27:7813\u201330.","journal-title":"World J Gastroenterol"},{"key":"4921_CR7","doi-asserted-by":"crossref","unstructured":"Ma Z, Li Z, Cao J, Sun J, Huang S, Zhou Q et al. What eliminates the chance for cure: a multi-center evaluation on 10-year follow-up of gallbladder cancer after surgical resection. Ann Med 56:2402072.","DOI":"10.1080\/07853890.2024.2402072"},{"key":"4921_CR8","doi-asserted-by":"publisher","first-page":"103328","DOI":"10.1016\/j.critrevonc.2021.103328","volume":"163","author":"AA Azizi","year":"2021","unstructured":"Azizi AA, Lamarca A, McNamara MG, Valle JW. Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;163:103328.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4921_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.suronc.2019.09.006","volume":"31","author":"EE Montalvo-Jave","year":"2019","unstructured":"Montalvo-Jave EE, Rahnemai- Azar AA, Papaconstantinou D, Deloiza ME, Tsilimigras DI, Moris D, et al. Molecular pathways and potential biomarkers in gallbladder cancer: A comprehensive review. Surg Oncol. 2019;31:83\u20139.","journal-title":"Surg Oncol"},{"key":"4921_CR10","first-page":"49","volume":"5","author":"K Verma","year":"2020","unstructured":"Verma K, Dixit R, Singh J, Tiwary SK, Khanna AK, Narayan G, et al. Molecular genetics changes in gallbladder carcinoma. Int J Mol Immuno Oncol. 2020;5:49\u201361.","journal-title":"Int J Mol Immuno Oncol"},{"key":"4921_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0377-4929.130849","volume":"57","author":"N Kumari","year":"2014","unstructured":"Kumari N, Corless CL, Warrick A, Beadling C, Nelson D, Neff T, et al. Mutation profiling in gallbladder cancer in Indian population. Indian J Pathol Microbiol. 2014;57:9\u201312.","journal-title":"Indian J Pathol Microbiol"},{"key":"4921_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-4.15476","volume":"42","author":"A Kumar","year":"2020","unstructured":"Kumar A, Gupta R, Mathur N, Iyer VK, Thulkar S, Prasad CP, et al. Microarray based gene expression profiling of advanced gall bladder cancer. Exp Oncol. 2020;42:277\u201384.","journal-title":"Exp Oncol"},{"key":"4921_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4143\/crt.2005.37.3.171","volume":"37","author":"WS Moon","year":"2005","unstructured":"Moon WS, Park HS, Lee H, Pai R, Tarnawski AS, Kim KR, et al. Co-Expression of Cox-2, C-Met and \u03b2-catenin in Cells Forming Invasive front of Gallbladder Cancer. Cancer Res Treat. 2005;37:171.","journal-title":"Cancer Res Treat"},{"key":"4921_CR14","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1007\/s13277-014-2876-y","volume":"36","author":"D Zhang","year":"2015","unstructured":"Zhang D, Wang Y, Dai Y, Wang J, Suo T, Pan H, et al. CIZ1 promoted the growth and migration of gallbladder cancer cells. Tumor Biol. 2015;36:2583\u201391.","journal-title":"Tumor Biol"},{"key":"4921_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/1319-3767.105922","volume":"19","author":"M Ghosh","year":"2013","unstructured":"Ghosh M, Sakhuja P, Singh S, Agarwal AK. p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer. Saudi J Gastroenterol Off J Saudi Gastroenterol Assoc. 2013;19:34\u20139.","journal-title":"Saudi J Gastroenterol Off J Saudi Gastroenterol Assoc"},{"key":"4921_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.18535\/jmscr\/v6i2.92","volume":"6","author":"D Chandrawati","year":"2018","unstructured":"Chandrawati D, Kumar S, Mitra S. Beta-Catenin Expression in Gallbladder Tissues and Its Role in Carcinogenesis and Tumor Progression in Gallbladder Carcinoma. J Med Sci Clin Res. 2018;6:591\u201399.","journal-title":"J Med Sci Clin Res"},{"key":"4921_CR17","first-page":"100173","volume":"23","author":"R Dixit","year":"2020","unstructured":"Dixit R, Pandey M, Tripathi SK, Dwivedi AND, Shukla VK. Genetic mutational analysis of \u03b2-catenin gene affecting GSK-3\u03b2 phosphorylation plays a role in gallbladder carcinogenesis: Results from a case control study. Cancer Treat Res Commun. 2020;23:100173.","journal-title":"Cancer Treat Res Commun"},{"key":"4921_CR18","first-page":"1","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7:1\u201323.","journal-title":"Signal Transduct Target Ther"},{"key":"4921_CR19","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.3390\/cells12182256","volume":"12","author":"C Li","year":"2023","unstructured":"Li C, Furth EE, Rustgi AK, Klein PS. When You Come to a Fork in the Road, Take It: Wnt Signaling Activates Multiple Pathways through the APC\/Axin\/GSK-3 Complex. Cells. 2023;12:2256.","journal-title":"Cells"},{"key":"4921_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald BT, Tamai K, He X. Wnt\/\u03b2-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9\u201326.","journal-title":"Dev Cell"},{"key":"4921_CR21","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3892\/ijo.2016.3360","volume":"48","author":"X Wu","year":"2016","unstructured":"Wu X, Luo F, Li J, Zhong X, Liu K. Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the Wnt signaling pathway. Int J Oncol. 2016;48:1333\u201340.","journal-title":"Int J Oncol"},{"key":"4921_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.yjmcc.2019.08.007","volume":"135","author":"L Zhao","year":"2019","unstructured":"Zhao L, Sun L, Lu Y, Li F, Xu H. A small-molecule LF3 abrogates \u03b2-catenin\/TCF4-mediated suppression of NaV1.5 expression in HL-1 cardiomyocytes. J Mol Cell Cardiol. 2019;135:90\u20136.","journal-title":"J Mol Cell Cardiol"},{"key":"4921_CR23","doi-asserted-by":"publisher","first-page":"bpab014","DOI":"10.1093\/biomethods\/bpab014","volume":"6","author":"M Aslan","year":"2021","unstructured":"Aslan M, Hsu E-C, Liu S, Stoyanova T. Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay. Biol Methods Protoc. 2021;6:bpab014.","journal-title":"Biol Methods Protoc"},{"key":"4921_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","volume":"81","author":"W Xue","year":"2024","unstructured":"Xue W, Yang L, Chen C, Ashrafizadeh M, Tian Y, Sun R. Wnt\/\u03b2-catenin-driven EMT regulation in human cancers. Cell Mol Life Sci CMLS. 2024;81:79.","journal-title":"Cell Mol Life Sci CMLS"},{"key":"4921_CR25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.febslet.2008.12.042","volume":"583","author":"Y Adachi","year":"2009","unstructured":"Adachi Y, Takeuchi T, Nagayama T, Ohtsuki Y, Furihata M. Zeb1-mediated T\u2010cadherin repression increases the invasive potential of gallbladder cancer. FEBS Lett. 2009;583:430\u20136.","journal-title":"FEBS Lett"},{"key":"4921_CR26","doi-asserted-by":"publisher","first-page":"17069","DOI":"10.1038\/cddiscovery.2017.69","volume":"3","author":"S Xu","year":"2017","unstructured":"Xu S, Zhan M, Wang J. Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks. Cell Death Discov. 2017;3:17069.","journal-title":"Cell Death Discov"},{"key":"4921_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-1-4939-7401-6_8","volume":"1692","author":"V Rajendran","year":"2018","unstructured":"Rajendran V, Jain MV. In Vitro Tumorigenic Assay: Colony Forming Assay for Cancer Stem Cells. Methods Mol Biol. 2018;1692:89\u201395.","journal-title":"Methods Mol Biol"},{"key":"4921_CR28","doi-asserted-by":"publisher","first-page":"71471","DOI":"10.18632\/oncotarget.17277","volume":"8","author":"CP Prasad","year":"2017","unstructured":"Prasad CP, S\u00f6dergren K, Andersson T. Reduced production and uptake of lactate are essential for the ability of WNT5A signaling to inhibit breast cancer cell migration and invasion. Oncotarget. 2017;8:71471\u201388.","journal-title":"Oncotarget"},{"key":"4921_CR29","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1080\/01635581.2021.1952628","volume":"74","author":"SM Umar","year":"2022","unstructured":"Umar SM, Patra S, Kashyap A, Dev JRA, Kumar L, Prasad CP. Quercetin Impairs HuR-Driven Progression and Migration of Triple Negative Breast Cancer (TNBC) Cells. Nutr Cancer. 2022;74:1497\u2013510.","journal-title":"Nutr Cancer"},{"key":"4921_CR30","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.annonc.2024.05.465","volume":"35","author":"A Kashyap","year":"2024","unstructured":"Kashyap A, Kumar S, Das P, Rajegowda C, Prasad CP. 322P Exploring the role of canonical WNT signaling in gallbladder cancer progression and therapeutic implications of XAV939. Ann Oncol. 2024;35:S134\u20135.","journal-title":"Ann Oncol"},{"key":"4921_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-025-02363-1","volume":"24","author":"X Wu","year":"2025","unstructured":"Wu X, Que H, Li Q, Wei X. Wnt\/\u03b2-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy. Mol Cancer. 2025;24:171.","journal-title":"Mol Cancer"},{"key":"4921_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s10238-025-01757-1","volume":"25","author":"E Saburi","year":"2025","unstructured":"Saburi E, Moghbeli M. \u03b2-catenin as a key regulator of the cisplatin response in tumor cells. Clin Exp Med. 2025;25:206.","journal-title":"Clin Exp Med"},{"key":"4921_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-025-02306-w","volume":"24","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang C-H, Li N. Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation. Mol Cancer. 2025;24:107.","journal-title":"Mol Cancer"},{"key":"4921_CR34","doi-asserted-by":"publisher","first-page":"33972","DOI":"10.18632\/oncotarget.15687","volume":"8","author":"S Shang","year":"2017","unstructured":"Shang S, Hua F, Hu Z-W. The regulation of \u03b2-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017;8:33972\u201389.","journal-title":"Oncotarget"},{"key":"4921_CR35","first-page":"6585","volume":"14","author":"W Guo","year":"2017","unstructured":"Guo W, Shen F, Xiao W, Chen J, Pan F. Wnt inhibitor XAV939 suppresses the viability of small cell lung cancer NCI-H446 cells and induces apoptosis. Oncol Lett. 2017;14:6585\u201391.","journal-title":"Oncol Lett"},{"key":"4921_CR36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1158\/0008-5472.CAN-15-1519","volume":"76","author":"L Fang","year":"2016","unstructured":"Fang L, Zhu Q, Neuenschwander M, Specker E, Wulf-Goldenberg A, Weis WI, et al. A Small-Molecule Antagonist of the \u03b2-Catenin\/TCF4 Interaction Blocks the Self-Renewal of Cancer Stem Cells and Suppresses Tumorigenesis. Cancer Res. 2016;76:891\u2013901.","journal-title":"Cancer Res"},{"key":"4921_CR37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/pcmr.12501","volume":"29","author":"Z Aktary","year":"2016","unstructured":"Aktary Z, Bertrand JU, Larue L. The WNT -less wonder: WNT \u2010independent \u03b2 \u2010catenin signaling. Pigment Cell Melanoma Res. 2016;29:524\u201340.","journal-title":"Pigment Cell Melanoma Res"},{"key":"4921_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","volume":"62","author":"N Krishnamurthy","year":"2018","unstructured":"Krishnamurthy N, Kurzrock R. Targeting the Wnt\/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev. 2018;62:50\u201360.","journal-title":"Cancer Treat Rev"},{"key":"4921_CR39","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.3390\/cancers14215468","volume":"14","author":"RWH Leung","year":"2022","unstructured":"Leung RWH, Lee TKW. Wnt\/\u03b2-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers. 2022;14:5468.","journal-title":"Cancers"},{"key":"4921_CR40","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1091\/mbc.E16-01-0058","volume":"27","author":"YI Petrova","year":"2016","unstructured":"Petrova YI, Schecterson L, Gumbiner BM. Roles for E-cadherin cell surface regulation in cancer. Mol Biol Cell. 2016;27:3233\u201344.","journal-title":"Mol Biol Cell"},{"key":"4921_CR41","doi-asserted-by":"publisher","first-page":"2005420","DOI":"10.1080\/21688370.2021.2005420","volume":"10","author":"SN Rubtsova","year":"2022","unstructured":"Rubtsova SN, Zhitnyak IY, Gloushankova NA. Dual role of E-cadherin in cancer cells. Tissue Barriers. 2022;10:2005420.","journal-title":"Tissue Barriers"},{"key":"4921_CR42","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1245\/s10434-010-1519-9","volume":"18","author":"L Wang","year":"2011","unstructured":"Wang L, Wang L, Yu Z, Chen B, Liu Y, Cheng H, et al. Prognostic Value of Nuclear \u03b2-catenin Overexpression at Invasive Front in Colorectal Cancer for Synchronous Liver Metastasis. Ann Surg Oncol. 2011;18:1553\u20139.","journal-title":"Ann Surg Oncol"},{"key":"4921_CR43","first-page":"6895","volume":"16","author":"MK Kim","year":"2018","unstructured":"Kim MK. Novel insight into the function of tankyrase. Oncol Lett. 2018;16:6895\u2013902.","journal-title":"Oncol Lett"},{"key":"4921_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3175","volume":"42","author":"KP Papadopoulos","year":"2024","unstructured":"Papadopoulos KP, Ahnert JR, Khushman MM, Sharma S, Pelster M, Cecchini M, et al. A first-in-human, phase 1\/2 trial of FOG-001, a \u03b2-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors. J Clin Oncol. 2024;42:16.","journal-title":"J Clin Oncol"},{"key":"4921_CR45","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.2025.43.4_suppl.286","volume":"43","author":"AB El-Khoueiry","year":"2025","unstructured":"El-Khoueiry AB, Lakhani NJ, Henry JT, Powell SF, Mettu NB, Gakuria J, et al. Safety and biomarker assessment of ST316, a novel peptide antagonist of \u00df-catenin, in patients with advanced solid tumors. J Clin Oncol. 2025;43:286\u2013286.","journal-title":"J Clin Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04921-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:12:38Z","timestamp":1783091558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04921-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4921"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04921-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. This study did not involve human participants or animals, and therefore no consent to participate was required. The work was done on well-established cell lines. This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"977"}}